neomycin sulfate + bacitracin zinc + lidocaine hydrochloride + polymyxin b sulfate

Neomycin sulfate + bacitracin zinc + lidocaine hydrochloride + polymyxin b sulfate is a **topical small-molecule combination drug** containing three antibacterial agents and one local anesthetic. Neomycin, an aminoglycoside, inhibits bacterial protein synthesis by binding the 30S ribosomal subunit; bacitracin interferes with bacterial cell wall synthesis by binding undecaprenyl pyrophosphate intermediates; polymyxin B disrupts Gram-negative bacterial membranes through interaction with lipopolysaccharides and phospholipids; and lidocaine blocks voltage-gated sodium channels to provide local analgesia. The combination is marketed primarily as an OTC first-aid cream or ointment for prevention of infection and temporary relief of pain or discomfort in minor cuts, scrapes, and burns. It is not a single-sponsor proprietary development asset but a widely marketed multisource topical formulation manufactured by multiple consumer healthcare and generic companies.

Brand names

RECELLTISTriple Antibiotic Plus Lidocaine

Other names

neomycin sulfate + bacitracin zinc + lidocaine hydrochloride + polymyxin b sulfatetriple antibiotic plus lidocainetopical triple antibiotic plus lidocaine